Table 1. Baseline characteristics and presence of follow up among the 673 enrolled women stratified by mRNA test result.

		mRNA test
		Negative		Positive		Invalid		Total
		N (row%) (col%)		N (row%) (col%)		N (row%) (col%)		N (row%) (col%)
Total		496 (73.7) (100)		150 (22.3) (100)		27 (4.0) (100)		673 (100) (100)
HR-HPV DNA
Negative		160 (98.2) (32.3)		3 (1.8) (2.0)		0 (0.0) (0.0)		163 (100) (24.2)
Positive		329 (65.8) (66.3)		144 (28.8) (96.0)		27 (5.4) (100)		500 (100) (74.3)
Not available		7 (70.0) (1.4)		3 (30.0) (2.0)		0 (0.0) (0.0)		10 (100) (1.5)
Cytology
NILM		137 (79.7) (27.6)		25 (14.5) (16.7)		10 (5.8) (37.0)		172 (100) (25.6)
ASC-US		93 (73.8) (18.8)		26 (20.6) (17.2)		7 (5.6) (26.0)		126 (100) (18.7)
L-SIL		244 (72.0) (49.2)		85 (25.1) (56.7)		10 (2.9) (37.0)		339 (100) (50.4)
ASC-H/H-SIL		14 (51.8) (2.8)		13 (48.2) (8.7)		0 (0.0) (0.0)		27 (100) (4.0)
Not available		8 (88.9) (1.6)		1 (11.1) (0.7)		0 (0.0) (0.0)		9 (100) (1.3)
Histology
no biopsy (negative colposcopy)		137 (77.0) (27.6)		30 (16.8) (20.0)		11 (6.2) (40.8)		178 (100) (26.5)
Unsatisfactory		0 (0.0) (0.0)		1 (100) (0.7)		0 (0.0) (0.0)		1 (100) (0.1)
negative biopsy		110 (76.4) (22.2)		28 (19.4) (18.7)		6 (4.2) (22.2)		144 (100) (21.4)
CIN1		249 (71.1) (50.2)		91 (26.0) (60.6)		10 (2.9) (37.0)		350 (100) (52.0)
presence of FU test
yes	250 (72.1) (50.4)		82 (23.6) (54.6)		15 (4.3) (55.6)		347 (100) (51.6)
not	246 (75.4) (49.6)		68 (20.9) (45.4)		12 (3.7) (44.4)		326 (100) (48.4)